2AALAEI-ANDABILI SH, ALAVIAN SM. Regulatory T cells are the most important determinant factor of hepatitis B infection proguosis : A systematic review and meta-analysis [ J ] . Vaccine, 2012 , 30 (38) : 5595 -5602.
3LV GC, MA WJ, YING LJ, et al. Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels [J] . World J Gastroenterol, 2010, 16 (32) : 4095 - 4099.
4DE NIET A, TAKKENBERG RB, BENAYED R, et al. Genetic vari- ation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and ade- fovir [J] . Scand J Gastroenterol, 2012, 47 (4): 475-481.
5KEEFFE EB, ZEUZEM S, KOFF RS, eta/. Report dan international workshop : Roadmap for management of patients receiving oral therapy for chronic hepatitis B [ J ] . Clin Gastroenterol Hepatol, 2007, 5 ( 8 ) : 890 - 897.
6DAS , A , MAINI MK. Innate and adaptive immune responses in hepati- tis B virus infection[J] . Dig Dis, 2010, 28 (1) : 126 -132.
7PENG G, LI, S WU W, et cd. Circulating CD4 + CD25 + regulatory T cells correlate with chronic hepatitis B infection [ J ] . Immunology, 2008, 123 (1): 57-65.
8SPRENGERS D, STOOP JN, BINDA RS , et al. Induction of regula- tory T-cells and interleukin-10-produeing cells in non-responders to pegylated interferon-alpha therapy for chronic hepatitis B [ J]. Antivir Ther, 2007, 12 (7) : 1087 -1096.
